Chapter-5

VAGINAL MICROBIOME AND HEALTH

[1]Anjali, [2]Dr. Suchandra Gupta

[1]Department of Medical Laboratory Technology and Biochemistry, School of Allied Health Sciences, SGT University, Gurugram, Haryana, India
[2]Assistant Professor, Department of Medical Laboratory Technology & Biochemistry, School of Allied Health Sciences, SGT University, Gurugram, India

LEARNING OBJECTIVES

1. Describe the composition and normal physiology of the vaginal microbiome, including the predominant role of Lactobacillus species in maintaining vaginal homeostasis and reproductive health.
2. Explain the major functions of the vaginal microbiome, including regulation of vaginal pH, prevention of pathogen colonization, maintenance of epithelial barrier integrity, immune modulation, metabolic activity, and support of reproductive health.
3. Identify the intrinsic and extrinsic factors that influence vaginal microbiome composition, such as hormonal changes, menstrual cycle, sexual activity, antibiotic exposure, immune status, ethnicity, lifestyle, and intimate hygiene practices.
4. Discuss the mechanisms and clinical consequences of vaginal dysbiosis, including its association with bacterial vaginosis, vulvovaginal candidiasis, sexually transmitted infections, pelvic inflammatory disease, adverse pregnancy outcomes, polycystic ovary syndrome, and endometriosis.
5. Compare the conventional and molecular diagnostic approaches used for evaluating the vaginal microbiome, including Amsel's criteria, Nugent scoring, Gram staining, PCR-based assays, 16S rRNA gene sequencing, and whole-genome sequencing.
6. Evaluate the impact of intimate hygiene practices and lifestyle behaviors on vaginal microbial balance, and recognize evidence-based recommendations for maintaining a healthy vaginal ecosystem.
7. Describe current preventive and therapeutic strategies for restoring vaginal microbial homeostasis, including probiotics, antimicrobial therapy, vaginal microbiota transplantation, and appropriate hygiene and lifestyle interventions.

5.1 INTRODUCTION

The vaginal microbiome is a highly specialized and dynamic microbial ecosystem composed of bacteria, fungi, viruses, and other microorganisms that naturally inhabit the vaginal tract. Among these, bacteria constitute the dominant component, with Lactobacillus species being the predominant microorganisms in healthy women of reproductive age. The vaginal microbiome plays an essential role in maintaining female reproductive and urogenital health by preserving the integrity of the vaginal mucosa, regulating immune responses, and preventing colonization by pathogenic microorganisms. A healthy vaginal ecosystem is generally characterized by low microbial diversity and the dominance of Lactobacillus species, which metabolize glycogen-derived carbohydrates into lactic acid, thereby maintaining an acidic vaginal pH of approximately 3.5–4.5. This acidic environment serves as a natural defense mechanism that inhibits the growth of pathogenic bacteria, fungi, and viruses while supporting the stability of beneficial microbial communities. [1] The composition and stability of the vaginal microbiome are influenced by numerous intrinsic and extrinsic factors throughout a woman's life.

Endogenous factors include age, hormonal status, menstrual cycle, pregnancy, menopause, host genetics, and immune function, whereas exogenous factors include sexual activity, hygiene practices, antibiotic use, contraceptive methods, diet, lifestyle, and environmental exposures. [2] Alterations in these factors may disrupt the balance of the vaginal microbial ecosystem, resulting in a condition known as vaginal dysbiosis, which is characterized by a reduction in Lactobacillus populations and an increase in diverse anaerobic microorganisms such as Gardnerella, Prevotella, Atopobium, and Mobiluncus species. [3] Vaginal dysbiosis has been strongly associated with several gynecological and obstetric disorders, including bacterial vaginosis, vulvovaginal candidiasis, sexually transmitted infections, pelvic inflammatory disease, infertility, recurrent urinary tract infections, and adverse pregnancy outcomes such as premature rupture of membranes and preterm birth. [1,4,5]

The understanding of the vaginal microbiome has evolved considerably over the past century. In 1892, the German gynecologist Albert Döderlein first described large Gram-positive rod-shaped bacteria in the vaginal secretions of healthy pregnant women, later referred to as Döderlein's bacilli. He recognized that these bacteria produced lactic acid, which maintained the acidic vaginal environment and protected against pathogenic microorganisms. In 1928, these organisms were classified as Lactobacillus acidophilus, marking an important milestone in understanding the protective role of lactobacilli in vaginal health. During the 1950s and 1980s, the work of Gardner and Dukes led to the identification of Haemophilus vaginalis, subsequently renamed Gardnerella vaginalis, as an important organism associated with bacterial vaginosis and abnormal vaginal discharge. In the 1980s and 1990s, researchers at the University of Washington further refined the concept of bacterial vaginosis by demonstrating that the condition resulted from a polymicrobial imbalance rather than infection by a single pathogen. The advent of culture-independent molecular technologies during the early 21st century, particularly 16S ribosomal RNA (16S rRNA) gene sequencing, revolutionized the study of the vaginal microbiome. These techniques enabled comprehensive characterization of vaginal microbial communities without the limitations of conventional culture methods, leading to the identification of distinct community state types (CSTs) and a deeper understanding of microbial diversity, lactic acid production, metabolic pathways, host–microbe interactions, and immune regulation. Advances in next-generation sequencing, metagenomics, metabolomics, and bioinformatics continue to expand knowledge regarding the complex relationships between the vaginal microbiome and female reproductive health, providing new opportunities for improved diagnosis, prevention, and personalized treatment of vaginal disorders.

5.2 HISTORICAL PERSPECTIVE ON VAGINAL HEALTH

The understanding of vaginal health has evolved remarkably over the past century, progressing from the recognition of a few dominant bacterial species to a comprehensive appreciation of the vaginal microbiome as a complex and dynamic microbial ecosystem. Early investigations primarily focused on identifying microorganisms responsible for maintaining vaginal health and preventing infections, whereas modern molecular techniques have revealed the remarkable diversity of microbial communities and their interactions with the host. One of the earliest milestones in vaginal microbiology was the discovery that healthy vaginal flora is predominantly composed of Lactobacillus species. These beneficial bacteria maintain the vaginal environment by producing lactic acid, thereby sustaining an acidic vaginal pH of approximately 3.5–4.5, which inhibits the growth of pathogenic microorganisms. [6] The protective role of lactobacilli was later explained through studies demonstrating that glycogen stored within vaginal epithelial cells serves as the primary energy source for these bacteria. Under the influence of estrogen, vaginal epithelial cells accumulate glycogen, which is metabolized by Lactobacillus species into lactic acid, preserving the acidic environment essential for microbial homeostasis. [7] A reduction in Lactobacillus populations disrupts this protective mechanism, leading to elevated vaginal pH and increased susceptibility to opportunistic infections. For many decades, bacterial vaginosis was considered to be caused primarily by Gardnerella vaginalis, formerly known as Haemophilus vaginalis. This concept dominated clinical practice because G. vaginalis was frequently isolated from women with abnormal vaginal discharge. However,

advances in microbiological and molecular research demonstrated that bacterial vaginosis is not caused by a single microorganism but represents a polymicrobial condition involving a complex consortium of anaerobic bacteria, including Gardnerella, Prevotella, Atopobium, Mobiluncus, Megasphaera, Sneathia, and several other anaerobic species that collectively replace the protective Lactobacillus-dominated microbiota. This paradigm shift significantly improved the understanding of vaginal dysbiosis and its relationship with reproductive health. The introduction of culture-independent molecular technologies, particularly 16S ribosomal RNA (16S rRNA) gene sequencing, revolutionized vaginal microbiome research by enabling comprehensive characterization of bacterial communities that could not be identified using conventional culture techniques. These studies led to the classification of vaginal microbial communities into Community State Types (CSTs). Community State Types I, II, III, and V are predominantly dominated by different Lactobacillus species, whereas Community State Type IV is characterized by reduced Lactobacillus abundance and increased microbial diversity with predominance of anaerobic bacteria, making it more closely associated with bacterial vaginosis and other dysbiotic conditions. Among the Lactobacillus species, Lactobacillus iners occupies a unique position because it is commonly detected in both healthy and dysbiotic vaginal environments, suggesting that its role may vary depending on the surrounding microbial community and host conditions.

Recent research has further expanded the understanding of vaginal microbial ecology by demonstrating that vaginal microbiome composition differs significantly among populations and ethnic groups. Large-scale sequencing studies have shown that microbial community structures are influenced not only by environmental and behavioral factors but also by genetic background, hormonal status, geography, and ethnicity. [8] For example, women of Asian and European ancestry more commonly exhibit microbiomes dominated by Lactobacillus crispatus or Lactobacillus iners, whereas women of African ancestry are more likely to exhibit diverse anaerobic microbial communities without necessarily showing signs of disease. These findings have challenged the traditional concept of a single "normal" vaginal microbiome and emphasize that vaginal health should be interpreted within the context of individual biological and population-specific variations. Overall, the historical development of vaginal microbiome research reflects a transition from culture-based identification of individual pathogens to advanced molecular characterization of complex microbial ecosystems. This evolving understanding has provided valuable insights into the mechanisms underlying vaginal health and disease and has paved the way for personalized diagnostic and therapeutic approaches in women's reproductive healthcare.

5.3 COMPOSITION OF THE VAGINAL MICROBIOME

The vaginal microbiome is a unique microbial ecosystem consisting of bacteria, fungi, viruses, and archaea that coexist within the vaginal environment. Compared with other mucosal sites of the human body, such as the gastrointestinal tract and oral cavity, the vagina harbors a relatively low microbial diversity but a high abundance of beneficial bacteria. In healthy women of reproductive age, the vaginal microbiome is typically dominated by Lactobacillus species, which account for more than 90% of the bacterial population. These beneficial microorganisms are essential for maintaining vaginal homeostasis, protecting against pathogenic microorganisms, and supporting normal reproductive function. [9]




Figure: 5.1 Composition of the Healthy Vaginal Microbiome

The predominant Lactobacillus species found in healthy women include Lactobacillus crispatus, Lactobacillus iners, Lactobacillus gasseri, and

Lactobacillus jensenii.Each species possesses distinct biological characteristics that influence the stability and protective capacity of the vaginal ecosystem. Among these, *Lactobacillus crispatus* is considered the most protective because it produces high concentrations of both D- and L-lactic acid, hydrogen peroxide, and bacteriocins, thereby creating an acidic environment that effectively suppresses the growth of pathogenic microorganisms. Women whose vaginal microbiota is dominated by *L. crispatus* generally exhibit greater microbial stability and a lower risk of bacterial vaginosis, sexually transmitted infections, and adverse pregnancy outcomes. *Lactobacillus gasseri* and *Lactobacillus jensenii* also contribute significantly to maintaining vaginal health by producing antimicrobial substances and preventing pathogen colonization. Among the Lactobacillus species, *Lactobacillus iners* exhibits unique characteristics. Unlike other Lactobacillus species, *L. iners* is frequently detected in both healthy and dysbiotic vaginal environments. Although it produces lactic acid, it synthesizes fewer protective antimicrobial compounds and possesses a smaller genome, enabling rapid adaptation to changing environmental conditions. Consequently, *L. iners* is often regarded as a transitional species that may persist during the shift between healthy and dysbiotic microbial states rather than providing the same level of protection as *L. crispatus*.[10] The composition of the vaginal microbiome has been systematically categorized into Community State Types (CSTs) based on culture-independent molecular techniques, particularly 16S ribosomal RNA (16S rRNA) gene sequencing. This classification has greatly enhanced the understanding of vaginal microbial diversity and its association with reproductive health.

Five major Community State Types have been identified:

- CST I: Dominated by *Lactobacillus crispatus*, representing the most stable and protective microbial community.
- CST II: Dominated by *Lactobacillus gasseri*, associated with a healthy vaginal environment.
- CST III: Dominated by *Lactobacillus iners*, often considered less stable and capable of transitioning toward dysbiosis.
- CST IV: Characterized by depletion of Lactobacillus species and predominance of diverse anaerobic bacteria such as *Gardnerella vaginalis, Atopobium vaginae, Prevotella, Mobiluncus, Sneathia, Megasphaera,* and other anaerobes. This community type is strongly associated with bacterial vaginosis, inflammation, increased vaginal pH, sexually transmitted infections, infertility, and adverse pregnancy outcomes.
- CST V: Dominated by *Lactobacillus jensenii*, representing another healthy and protective vaginal microbial community.

Unlike the gastrointestinal microbiome, which contains thousands of bacterial species, the vaginal microbiome exhibits relatively low bacterial diversity under healthy conditions. This low diversity is beneficial because the dominance of Lactobacillus species maintains an acidic vaginal pH (3.5–4.5), produces antimicrobial compounds, and competitively excludes pathogenic microorganisms. Conversely, increased microbial diversity is generally considered a hallmark of vaginal dysbiosis and is associated with numerous gynecological disorders. Although bacteria represent the major constituents of the vaginal microbiome, other microorganisms are also present in smaller numbers. The vaginal mycobiome primarily consists of Candida species, particularly *Candida albicans*, which normally exist as harmless commensals but may become opportunistic pathogens under conditions of microbial imbalance or immune suppression. Similarly, the vaginal virome contains bacteriophages and human viruses, including human papillomavirus (HPV) and herpes simplex virus (HSV), whose persistence and pathogenicity may be influenced by alterations in the bacterial microbiome. Emerging evidence also suggests that archaea and protozoa may contribute to the vaginal microbial ecosystem, although their roles remain incompletely understood.

Recent advances in metagenomics, transcriptomics, metabolomics, and bioinformatics have demonstrated that the vaginal microbiome is highly dynamic rather than static. Its composition varies with age, hormonal fluctuations, menstrual cycle, pregnancy, menopause, ethnicity, sexual behavior, hygiene practices, antibiotic exposure, and host immune status. These factors continuously influence microbial composition and functional activity, emphasizing that vaginal health depends not only

on the presence of beneficial microorganisms but also on the maintenance of a balanced and resilient microbial ecosystem. Overall, the vaginal microbiome represents a highly specialized microbial community in which Lactobacillus species play a dominant protective role. The balance between beneficial lactobacilli and opportunistic microorganisms is fundamental to maintaining vaginal health, preventing infections, supporting normal reproductive function, and preserving overall female reproductive well-being.

5.4 FUNCTIONS OF THE VAGINAL MICROBIOME

The vaginal microbiome plays a fundamental role in maintaining female reproductive and urogenital health. In healthy women, the microbiota is predominantly composed of Lactobacillus species, which create a protective environment through the production of lactic acid and other antimicrobial substances. These microorganisms regulate vaginal pH, inhibit the growth of pathogenic organisms, strengthen the epithelial barrier, modulate local immune responses, support reproductive health, and contribute to metabolic activities within the vaginal ecosystem. Collectively, these functions preserve microbial homeostasis and reduce the risk of infections and adverse reproductive outcomes.

Table: 5.1 Function of vaginal microbiome

Function	Role in Vaginal Health
Maintenance of Vaginal pH	Lactobacillus species metabolize glycogen into lactic acid, maintaining an acidic vaginal pH (3.5–4.5) that inhibits the growth of pathogenic microorganisms. (1,6)
Protection Against Pathogens	Produces lactic acid, hydrogen peroxide (H_2O_2), and bacteriocins that suppress pathogens such as *Gardnerella vaginalis*, *Escherichia coli*, and *Candida* species while competing for epithelial adhesion sites. (6)
Barrier Function and Epithelial Integrity	Strengthens epithelial tight junctions, enhances mucosal barrier function, and supports tissue repair, reducing microbial invasion. (11)
Immune System Modulation	Regulates cytokines, chemokines, and antimicrobial peptides to maintain immune homeostasis while limiting excessive inflammation. (7)
Support of Reproductive Health	Promotes fertility, maintains a stable microbial environment during pregnancy, and reduces the risk of bacterial vaginosis, preterm birth, and other pregnancy complications. (12)
Metabolic Functions	Produces metabolites that influence nutrient availability, host cell signaling, and microbial interactions, thereby maintaining the stability of the vaginal ecosystem. (12)

5.5 DETERMINANTS OF VAGINAL MICROBIOME COMPOSITION

The composition and stability of the vaginal microbiome are influenced by a combination of biological, hormonal, environmental, and behavioral factors. These determinants regulate the abundance of Lactobacillus species and influence susceptibility to microbial dysbiosis and vaginal infections. Variations in hormone levels, immune function, antibiotic use, sexual practices, lifestyle, and ethnicity contribute to changes in microbial diversity and vaginal health.

Table: 5.2 Determinants of Vaginal Microbiome

Determinant	Influence on the Vaginal Microbiome
Hormonal Factors	Estrogen stimulates glycogen accumulation in vaginal epithelial cells, providing nutrients for *Lactobacillus* species to produce lactic acid. During puberty and pregnancy, higher estrogen levels promote Lactobacillus dominance, whereas menopause-associated estrogen decline reduces Lactobacillus abundance and increases microbial diversity.
Menstrual Cycle	Fluctuations in estrogen and progesterone during the menstrual cycle influence microbial composition. The vaginal microbiome is generally more stable during ovulation, while greater variability is observed during the follicular and menstrual phases.
Sexual Activity	Unprotected vaginal intercourse introduces exogenous microorganisms and alkaline semen, temporarily increasing vaginal pH and altering microbial

	composition, which may favor *Lactobacillus iners* or *Gardnerella vaginalis*.
Antibiotic Exposure	Broad-spectrum antibiotics reduce beneficial *Lactobacillus* populations, allowing opportunistic anaerobic bacteria such as *Prevotella* and *Bacteroides* to proliferate, thereby increasing the risk of dysbiosis.
Immune Status	Local immune responses regulate microbial colonization through cytokines, antimicrobial peptides, and inflammatory mediators. Altered immune function can disturb microbial balance and increase susceptibility to bacterial vaginosis and other infections.
Behavioral and Hygiene Practices	Lifestyle factors, intimate hygiene practices, vaginal douching, smoking, and personal hygiene behaviors can modify the vaginal environment and influence microbial stability.
Ethnicity and Genetics	Vaginal microbial composition differs among ethnic populations. *Lactobacillus crispatus* and *L. iners* are more prevalent in Asian and White women, whereas anaerobic bacteria associated with bacterial vaginosis are more frequently observed in African women, suggesting contributions from both genetic and environmental factors.

5.6 DYSBIOSIS AND DISEASE ASSOCIATIONS

The vaginal microbiome is normally dominated by Lactobacillus species, which maintain an acidic vaginal environment (pH 3.5–4.5), inhibit pathogen colonization, strengthen epithelial barrier integrity, and regulate local immune responses. Disruption of this balanced microbial ecosystem, known as vaginal dysbiosis, is characterized by depletion of Lactobacillus species and proliferation of diverse anaerobic microorganisms. This microbial imbalance increases vaginal pH, promotes inflammation, weakens mucosal defenses, and increases susceptibility to reproductive tract infections and adverse gynecological and obstetric outcomes. Increasing evidence indicates that vaginal dysbiosis contributes to several disorders, including bacterial vaginosis, sexually transmitted infections, vulvovaginal candidiasis, pelvic inflammatory disease, pregnancy complications, polycystic ovary syndrome (PCOS), and endometriosis. [1,3]

5.6.1 Bacterial Vaginosis (BV)

Bacterial vaginosis (BV) is the most common vaginal dysbiosis syndrome and results from the replacement of protective Lactobacillus species by a polymicrobial community of anaerobic bacteria, including *Gardnerella vaginalis, Prevotella spp., Mobiluncus spp., Megasphaera spp.*, and *Sneathia spp.*[3] The reduction in lactic acid production increases vaginal pH, facilitating biofilm formation and pathogen colonization. Clinically, BV presents with thin white or gray vaginal discharge, a characteristic fishy odor, vaginal irritation, and burning during urination. Although some women remain asymptomatic, untreated BV significantly increases the risk of pelvic inflammatory disease, sexually transmitted infections (including HIV), infertility, and adverse pregnancy outcomes such as preterm birth. [4] Diagnosis is commonly based on Amsel's criteria, Nugent scoring of Gram-stained smears, vaginal pH measurement, and wet-mount microscopy. Standard treatment includes oral or topical metronidazole, clindamycin, tinidazole, or secnidazole.

5.6.2 Sexually Transmitted Infections (STIs)

A healthy Lactobacillus-dominated microbiome provides an important defense against sexually transmitted pathogens by maintaining an acidic environment and preventing pathogen adherence. Dysbiosis compromises these protective mechanisms, increasing susceptibility to infections such as syphilis, gonorrhea, chlamydia, trichomoniasis, human immunodeficiency virus (HIV), human papillomavirus (HPV), hepatitis B virus, and herpes simplex virus. [15] Clinical manifestations vary depending on the causative organism and may include abnormal genital discharge, genital ulcers or blisters, dysuria, pelvic pain, itching, and abnormal vaginal bleeding. Laboratory diagnosis relies on nucleic acid amplification tests (NAATs), polymerase chain reaction (PCR), microbial culture, or

serological assays. Management consists of pathogen-specific antimicrobial or antiviral therapy together with strategies aimed at restoring a healthy vaginal microbiome.

5.6.3 Vulvovaginal Candidiasis (VVC)

Vulvovaginal candidiasis is a fungal infection predominantly caused by *Candida albicans*. Although *Candida* species normally exist as commensal organisms, disruption of the vaginal microbiome following antibiotic use, hormonal changes, pregnancy, or immunosuppression promotes fungal overgrowth. [6] Patients typically present with intense vulvar itching, soreness, erythema, thick white curd-like discharge, and burning during urination or sexual intercourse. Diagnosis is confirmed using potassium hydroxide (10% KOH) microscopy and fungal culture when necessary. Most infections respond well to oral fluconazole or topical azole antifungal agents, whereas recurrent infections may require prolonged therapy or boric acid preparations.

5.6.4 Pelvic Inflammatory Disease (PID)

Pelvic inflammatory disease is a serious ascending infection involving the uterus, fallopian tubes, ovaries, and surrounding pelvic tissues. Vaginal dysbiosis facilitates the migration of pathogenic microorganisms from the lower genital tract into the upper reproductive tract, particularly when accompanied by sexually transmitted infections. [17] Clinical manifestations include lower abdominal pain, fever, abnormal vaginal discharge, irregular menstrual bleeding, dysuria, nausea, and vomiting. Diagnosis is based on pelvic examination, microbiological testing for sexually transmitted pathogens, ultrasonography, and occasionally laparoscopy. Early administration of broad-spectrum antibiotics is essential to prevent complications such as infertility, ectopic pregnancy, and chronic pelvic pain.

5.6.5 Adverse Pregnancy Outcomes

Pregnancy is normally associated with increased dominance of Lactobacillus species due to elevated estrogen levels and increased glycogen availability within the vaginal epithelium. These physiological changes enhance lactic acid production, maintain an acidic vaginal environment, and provide protection against pathogenic microorganisms. [18-20] However, disruption of this microbial balance can result in bacterial vaginosis and other infections associated with preterm labor, premature rupture of membranes, low birth weight, neonatal infections, and altered neonatal microbiome development. Maintenance of a healthy vaginal microbiome through appropriate prenatal care, balanced nutrition, good hygiene practices, and timely treatment of infections is therefore essential for favorable maternal and neonatal outcomes.

5.6.6 Polycystic Ovary Syndrome (PCOS)

Polycystic ovary syndrome (PCOS) is an endocrine disorder characterized by hormonal imbalance, insulin resistance, chronic inflammation, and reproductive dysfunction. Emerging evidence suggests that women with PCOS exhibit significant alterations in the vaginal microbiome, including reduced abundance of Lactobacillus species and increased colonization by *Gardnerella, Atopobium, Mycoplasma, Candida, Prevotella,* and *Ureaplasma* species. [21-27] These microbial alterations may increase susceptibility to bacterial vaginosis, vulvovaginal candidiasis, infertility, and recurrent reproductive tract infections. Molecular studies using 16S rRNA sequencing have demonstrated reduced microbial stability in women with PCOS, although the causal relationship between dysbiosis and PCOS remains uncertain. Current management focuses on hormonal regulation, treatment of insulin resistance, lifestyle modification, management of vaginal infections, and investigation of microbiome-targeted therapies.

5.6.7 Endometriosis

Endometriosis is a chronic inflammatory gynecological disorder in which endometrial tissue grows outside the uterine cavity. Recent microbiome research indicates that women with endometriosis often exhibit decreased Lactobacillus dominance together with increased abundance of inflammatory and pathogenic microorganisms. [28] These microbial alterations may contribute to persistent inflammation, immune dysregulation, altered estrogen metabolism, and impaired clearance of ectopic endometrial tissue, thereby promoting disease progression. Clinically, endometriosis presents with chronic pelvic pain, dysmenorrhea,

dyspareunia, infertility, and reduced quality of life. Diagnosis is established through clinical evaluation, imaging studies, and laparoscopic examination. Although current treatment primarily consists of hormonal therapy and surgery, microbiome-directed therapeutic approaches are emerging as promising future strategies.

Table: 5.3 Major Clinical Conditions Associated with Vaginal Dysbiosis

Condition	Principal Microbial Alteration	Major Clinical Significance
Bacterial vaginosis	Loss of *Lactobacillus* with anaerobic overgrowth	Vaginal discharge, elevated pH, increased STI and pregnancy risks
Sexually transmitted infections	Impaired mucosal defense due to dysbiosis	Increased susceptibility to bacterial and viral STIs
Vulvovaginal candidiasis	Overgrowth of *Candida albicans* after microbial imbalance	Vulvar itching, white discharge, recurrent fungal infection
Pelvic inflammatory disease	Ascending polymicrobial infection	Infertility, chronic pelvic pain, ectopic pregnancy
Pregnancy complications	Reduced *Lactobacillus* dominance during dysbiosis	Preterm birth, premature rupture of membranes, neonatal complications
Polycystic ovary syndrome	Reduced *Lactobacillus* with increased opportunistic organisms	Recurrent infections, infertility, metabolic dysfunction
Endometriosis	Increased inflammatory microbiota and reduced *Lactobacillus*	Chronic inflammation, pelvic pain, infertility

5.7 DIAGNOSIS OF VAGINAL MICROBIOME DISORDERS

Accurate diagnosis of vaginal microbiome disorders requires integration of clinical findings with laboratory and molecular techniques. Conventional methods remain the cornerstone of routine clinical practice, whereas advanced molecular technologies provide comprehensive characterization of microbial communities and improved diagnostic accuracy.

Table: 5.4 Diagnostic Methods for Vaginal Microbiome Disorders

Method	Primary Application
Amsel's criteria	Clinical diagnosis of bacterial vaginosis
Gram stain and Nugent score	Laboratory gold standard for BV diagnosis
OSOM BV Blue test	Detection of bacterial sialidase activity
FemExam card	Rapid assessment using multiple BV biomarkers
qPCR	Highly sensitive identification and quantification of pathogens
16S rRNA sequencing	Comprehensive bacterial community profiling
Whole-genome sequencing	Functional and metagenomic analysis of the vaginal microbiome

Amsel's criteria remain one of the most widely used bedside diagnostic methods for bacterial vaginosis. Diagnosis is established when at least three of four findings are present: homogeneous vaginal discharge, vaginal pH greater than 4.5, clue cells on microscopy, and a positive whiff test following the addition of 10% potassium hydroxide.[29] Although rapid and inexpensive, the method is operator dependent. Gram staining combined with the Nugent scoring system remains the laboratory reference standard for diagnosing bacterial vaginosis. Nugent scores of 0–3 indicate normal flora, 4–6 represent intermediate flora, and 7–10 are diagnostic of bacterial vaginosis.[30] Additional rapid diagnostic tests, including the OSOM BV Blue test and FemExam card, detect bacterial enzymes and biochemical markers associated with BV and provide convenient point-of-care diagnosis.

Molecular diagnostic techniques have significantly advanced vaginal microbiome analysis. Quantitative polymerase chain reaction (qPCR) detects and quantifies specific bacterial DNA with high sensitivity and specificity, enabling identification of organisms such as *Gardnerella vaginalis*, *Atopobium vaginae*, and *Candida albicans* while estimating microbial load. [31] 16S rRNA gene sequencing offers culture-independent profiling of the entire bacterial community and enables classification

into Community State Types (CSTs), making it invaluable for microbiome research. [32] Whole-genome metagenomic sequencing provides the most comprehensive assessment by simultaneously identifying bacteria, fungi, viruses, antimicrobial resistance genes, and microbial metabolic pathways. Although these advanced molecular approaches remain largely confined to research and specialized laboratories due to cost and technical complexity, they represent the future of precision diagnosis and personalized microbiome-based therapy

5.8 IMPACT OF INTIMATE HYGIENE

PracticesIntimate hygiene practices play a significant role in maintaining or disrupting the vaginal microbiome. A healthy vaginal ecosystem is primarily sustained by Lactobacillus species, which maintain an acidic pH and inhibit the growth of pathogenic microorganisms. Appropriate hygiene practices help preserve this microbial balance, whereas excessive cleansing, inappropriate hygiene products, and certain behavioral habits can disturb the vaginal environment, leading to dysbiosis and an increased risk of infections. [33] Excessive washing of the external genital area, particularly with harsh soaps, antiseptics, or alkaline cleansing agents, can remove protective vaginal secretions and reduce the abundance of Lactobacillus species. This disruption elevates vaginal pH, weakens the natural defense mechanisms, and facilitates colonization by opportunistic pathogens. [34] Similarly, scented soaps, vaginal sprays, deodorants, and perfumed wipes contain chemical irritants that may damage the vaginal mucosa, alter the microbial community, and promote inflammation and microbial imbalance. [35] Clothing habits also influence vaginal microbial homeostasis. Wearing tight-fitting garments or non-breathable synthetic underwear increases local temperature and moisture, creating favorable conditions for the proliferation of opportunistic microorganisms, particularly *Candida* species, thereby increasing the risk of vulvovaginal candidiasis. [36] Maintaining good menstrual hygiene by changing sanitary pads or tampons regularly and using clean, absorbent menstrual products helps minimize bacterial overgrowth and supports microbial stability throughout the menstrual cycle. [37] Sexual hygiene practices have an additional impact on the vaginal microbiome. Seminal fluid has an alkaline pH that can temporarily increase vaginal pH and alter microbial composition following unprotected sexual intercourse. The consistent use of barrier contraceptives, such as condoms, reduces exposure to foreign microorganisms and helps preserve the normal vaginal microbial ecosystem. [38] Likewise, indiscriminate or prolonged antibiotic therapy may eliminate beneficial Lactobacillus species together with pathogenic bacteria, resulting in dysbiosis and increasing the likelihood of recurrent bacterial vaginosis or vulvovaginal candidiasis. [39] One of the most harmful hygiene practices is vaginal douching, which involves flushing the vagina with water or other cleansing solutions. Douching mechanically removes protective Lactobacillus populations, alters vaginal pH, and may introduce external microorganisms into the vaginal canal. Numerous studies have associated this practice with bacterial vaginosis, pelvic inflammatory disease, sexually transmitted infections, and adverse pregnancy outcomes. [40] Likewise, commercially available intimate hygiene products containing fragrances, antiseptics, or antimicrobial chemicals may disturb the natural microbial balance and irritate the vaginal mucosa, thereby increasing susceptibility to infection.[41] The resulting elevation in vaginal pH weakens the natural protective barrier and facilitates colonization by pathogenic microorganisms. [42]

Table: 5.5 Factors Affecting Vaginal Microbiome Through Intimate Hygiene Practices

Hygiene Practice	Effect on Vaginal Microbiome	Clinical Consequences
Excessive genital washing	Reduces Lactobacillus and increases vaginal pH	Increased susceptibility to bacterial vaginosis and other infections
Harsh soaps and antiseptics	Damages mucosal barrier and disrupts microbial balance	Irritation, inflammation, dysbiosis
Scented hygiene products	Alters normal vaginal flora through chemical irritation	Increased risk of vaginal infections
Tight synthetic clothing	Increases heat and moisture	Promotes *Candida* overgrowth and vulvovaginal candidiasis

Poor menstrual hygiene	Encourages microbial proliferation	Increased risk of bacterial and fungal infections
Unprotected sexual intercourse	Temporary elevation of vaginal pH and microbial alteration	Greater susceptibility to sexually transmitted infections
Excessive antibiotic use	Eliminates beneficial Lactobacillus species	Dysbiosis, recurrent bacterial vaginosis, candidiasis
Vaginal douching	Removes protective bacteria and disrupts vaginal pH	Bacterial vaginosis, pelvic inflammatory disease, adverse pregnancy outcomes

Overall, maintaining appropriate intimate hygiene is essential for preserving the vaginal microbiome and preventing dysbiosis-related disorders. Evidence-based practices, including gentle cleansing of the external genital area, avoidance of douching and fragranced hygiene products, appropriate menstrual hygiene, judicious antibiotic use, and safe sexual practices, are fundamental for sustaining vaginal microbial homeostasis and promoting female reproductive health.

5.9 PREVENTIVE AND THERAPEUTIC STRATEGIES

The prevention and management of vaginal microbiome-associated disorders are primarily aimed at maintaining or restoring a Lactobacillus-dominated vaginal ecosystem. A healthy vaginal microbiome preserves an acidic pH, strengthens mucosal barrier function, inhibits colonization by pathogenic microorganisms, and supports normal immune responses. Therapeutic interventions therefore focus not only on eliminating pathogenic organisms but also on re-establishing microbial homeostasis to reduce recurrence and improve reproductive health outcomes. [43,44] One of the most promising microbiome-directed interventions is the use of probiotics, particularly formulations containing *Lactobacillus* species such as *L. crispatus, L. rhamnosus,* and *L. reuteri*. These beneficial microorganisms help restore normal vaginal flora by producing lactic acid, lowering vaginal pH, inhibiting pathogen adhesion, and modulating local immune responses. Clinical studies suggest that probiotic supplementation, either orally or intravaginally, may reduce recurrence of bacterial vaginosis and vulvovaginal candidiasis, particularly when used as an adjunct to conventional antimicrobial therapy. Appropriate intimate hygiene practices are equally important for maintaining microbial balance. Vaginal douching, excessive cleansing, and the use of scented soaps, antiseptics, or perfumed hygiene products should be avoided because they disrupt the normal vaginal microbiota and increase susceptibility to bacterial vaginosis and other infections. [45,46] Instead, gentle cleansing of the external genital area using mild, unscented products is recommended to preserve the natural protective microbial community. Lifestyle modifications also contribute significantly to vaginal health. Wearing breathable cotton underwear, avoiding tight-fitting synthetic clothing, maintaining proper menstrual hygiene through regular changing of sanitary products, and practicing safe sexual behaviors such as consistent condom use help reduce exposure to pathogenic microorganisms and maintain microbial stability. [47,48]

Furthermore, unnecessary or prolonged antibiotic use should be avoided, as broad-spectrum antibiotics may eliminate beneficial Lactobacillus species and promote dysbiosis and recurrent infections. [49] Dietary factors may also influence vaginal microbial composition. A balanced diet rich in fiber, vitamins, minerals, and fermented foods, together with probiotic supplementation where appropriate, supports the growth of beneficial microorganisms and enhances overall reproductive health. [50] Regular gynecological examinations, early diagnosis and treatment of vaginal infections, and effective management of underlying conditions such as diabetes mellitus, hormonal disorders, or immunosuppression further reduce the risk of recurrent dysbiosis and associated complications. [51] Emerging therapeutic approaches are expanding beyond conventional antimicrobial treatment. Vaginal microbiota transplantation (VMT) has shown encouraging preliminary results for women with recurrent or treatment-resistant bacterial vaginosis by restoring a healthy microbial ecosystem from carefully screened donors. Other investigational strategies include personalized microbiome-based therapies, targeted probiotics, bacteriophage therapy, and precision antimicrobial approaches

designed to selectively eliminate pathogenic organisms while preserving beneficial bacteria. Although these therapies remain under active investigation, they represent promising future directions for improving long-term vaginal health and reducing disease recurrence.

Table: 5.6 Preventive and Therapeutic Strategies for Maintaining Vaginal Microbiome Health

Strategy	Mechanism of Action	Clinical Benefit
Probiotic therapy	Restores *Lactobacillus* populations and lowers vaginal pH	Reduces recurrence of bacterial vaginosis and candidiasis
Avoidance of vaginal douching	Preserves normal vaginal microbiota	Prevents dysbiosis and bacterial vaginosis
Use of mild, fragrance-free hygiene products	Minimizes chemical irritation and microbial disruption	Maintains healthy vaginal flora
Proper intimate and menstrual hygiene	Reduces microbial contamination and excessive moisture	Lowers risk of bacterial and fungal infections
Safe sexual practices	Limits exposure to sexually transmitted pathogens	Preserves microbial stability and reproductive health
Judicious antibiotic use	Prevents unnecessary depletion of beneficial bacteria	Reduces dysbiosis and recurrent infections
Healthy diet and probiotics	Supports beneficial microbial growth and immune function	Promotes long-term vaginal health
Regular gynecological care	Enables early diagnosis and management of infections	Prevents complications and disease recurrence
Emerging microbiome therapies (VMT, targeted probiotics)	Restores healthy microbial communities	Promising treatment for recurrent or refractory dysbiosis

Overall, successful prevention and treatment of vaginal microbiome-associated disorders require a combination of evidence-based hygiene practices, healthy lifestyle modifications, appropriate antimicrobial therapy, probiotic supplementation, and emerging microbiome-directed interventions. These integrated strategies aim to restore microbial balance, reduce disease recurrence, and improve both reproductive and overall women's health.

5.10 FUTURE PERSPECTIVES

Research on the vaginal microbiome has expanded rapidly over the past decade, revealing its fundamental role in female reproductive health and disease. However, many aspects of host–microbiome interactions, microbial metabolism, and disease pathogenesis remain poorly understood. Future research should therefore emphasize longitudinal cohort studies to better understand temporal changes in the vaginal microbiome throughout different stages of life, including puberty, pregnancy, menopause, and various gynecological disorders. Such studies will improve understanding of microbial dynamics and facilitate early identification of dysbiosis before the onset of clinical disease. [52] Advances in molecular diagnostic technologies, particularly 16S rRNA gene sequencing, shotgun metagenomic sequencing, and other next-generation sequencing (NGS) approaches, are expected to transform the diagnosis and management of vaginal microbiome-associated disorders. These technologies provide comprehensive characterization of microbial communities, enabling earlier detection of microbial imbalance and more accurate differentiation between healthy and dysbiotic states. As sequencing technologies become more affordable and clinically accessible, they are likely to become an integral component of precision diagnostics and personalized patient care.[53]

Another promising area of investigation is the development of microbiome-targeted therapeutic strategies. Next-generation probiotics containing carefully selected Lactobacillus strains with enhanced colonization ability may provide more effective restoration of the normal vaginal microbiota and reduce recurrence of bacterial vaginosis and vulvovaginal candidiasis. [54] In

addition, vaginal microbiota transplantation (VMT) has emerged as an innovative therapeutic approach for recurrent or treatment-resistant dysbiosis. Although preliminary clinical studies have demonstrated encouraging outcomes, larger randomized clinical trials are required to establish long-term safety, efficacy, donor selection criteria, and standardized treatment protocols. [55] Future investigations should also integrate microbiome research with endocrinology, immunology, and metabolic medicine. Conditions such as polycystic ovary syndrome (PCOS), endometriosis, obesity, diabetes mellitus, and pregnancy-related disorders are increasingly recognized as being influenced by complex interactions between hormonal regulation, immune responses, and microbial composition. Understanding these interactions may facilitate the development of personalized therapeutic strategies targeting both systemic and local mechanisms of disease. [56]

The application of emerging multi-omics technologies, including metabolomics, proteomics, transcriptomics, and metabolite profiling, will provide deeper insight into the functional activities of vaginal microbial communities rather than merely identifying microbial species. These approaches may lead to the discovery of novel biomarkers for early diagnosis, disease monitoring, prognosis, and treatment response. [57] Furthermore, the integration of artificial intelligence (AI), machine learning, and advanced bioinformatics will enable analysis of complex microbiome datasets, improve disease prediction models, identify personalized microbial signatures, and support clinical decision-making. From a public health perspective, future efforts should focus on developing evidence-based clinical guidelines for intimate hygiene practices, rational antibiotic prescribing, probiotic supplementation, and microbiome preservation. Patient education regarding appropriate genital hygiene, safe sexual practices, and lifestyle modifications will remain essential components of preventive healthcare. Ultimately, future clinical management is expected to shift from conventional broad-spectrum antimicrobial therapy toward precision microbiome-based medicine, providing individualized prevention and treatment strategies that improve reproductive health outcomes while reducing recurrent infections and antimicrobial resistance.

5.11 CONCLUSION

The vaginal microbiome represents a highly specialized and dynamic microbial ecosystem that plays a fundamental role in maintaining female reproductive health. Under physiological conditions, the vaginal environment is dominated by Lactobacillus species, which preserve an acidic pH, inhibit pathogen colonization, maintain epithelial barrier integrity, and regulate local immune responses. This delicate microbial balance is continuously influenced by hormonal fluctuations, age, sexual activity, hygiene practices, medication use, pregnancy, and host genetic factors. Disruption of this equilibrium, commonly referred to as vaginal dysbiosis, has been strongly associated with numerous gynecological and obstetric disorders, including bacterial vaginosis, vulvovaginal candidiasis, sexually transmitted infections, pelvic inflammatory disease, adverse pregnancy outcomes, polycystic ovary syndrome, and endometriosis.

Recent advances in molecular microbiology, particularly 16S rRNA gene sequencing, metagenomics, and other high-throughput sequencing technologies, have substantially expanded our understanding of vaginal microbial diversity and its relationship with human health. These discoveries have demonstrated that healthy vaginal microbiomes vary among individuals and populations, emphasizing the importance of personalized approaches to diagnosis and treatment. Emerging therapeutic strategies, including targeted probiotics, vaginal microbiota transplantation, and precision microbiome-based interventions, offer promising alternatives to conventional antimicrobial therapies, although additional large-scale clinical studies are required to establish their long-term safety and effectiveness. The continued interdisciplinary research integrating microbiology, immunology, reproductive medicine, genomics, and bioinformatics will further clarify the complex interactions between the host and vaginal microbiome. The translation of microbiome science into routine clinical practice has the potential to revolutionize preventive healthcare, improve early disease detection, reduce recurrent infections, and enable personalized therapeutic strategies. Maintaining a healthy vaginal microbiome through evidence-based hygiene practices, appropriate medical management, and

microbiome-directed interventions will remain essential for optimizing women's reproductive health and overall well-being.

REFERENCES

1. Martin DH. The microbiota of the vagina and its influence on women's health and disease. Am J Med Sci. 2012;343(1):2–9.
2. Menard JP. Antibacterial treatment of bacterial vaginosis: current and emerging therapies. Int J Womens Health. 2011;3:295–305.
3. Hickey RJ, Zhou X, Pierson JD, Ravel J, Forney LJ. Understanding vaginal microbiome complexity from an ecological perspective. Transl Res. 2012;160(4):267–282.
4. Ma B, Forney LJ, Ravel J. Vaginal microbiome: rethinking health and disease. Annu Rev Microbiol. 2020;74:371–389.
5. Auriemma RS, Scairati R, Del Vecchio G, et al. The vaginal microbiome: a long urogenital colonization throughout a woman's life. Front Cell Infect Microbiol. 2021;11:686167.
6. Schlabritz-Loutsevitch N, Gygax S, Dick E, et al. Vaginal dysbiosis from an evolutionary perspective. Sci Rep. 2016;6:26817.
7. France M, Alizadeh M, Brown S, et al. Towards a deeper understanding of the vaginal microbiota. Nat Microbiol. 2022;7(3):367–378.
8. Dong W, Wang S, Wang X, et al. Characteristics of vaginal microbiota of women of reproductive age with infections. Microorganisms. 2024;12(5):1030.
9. Condori-Catachura S, Ahannach S, Ticlla M, et al. Diversity in women and their vaginal microbiota. Trends Microbiol. 2025;33(11):1163–1172.
10. Liptáková A, Čurová K, Záhumenský J, et al. Microbiota of female genital tract: functional overview. Physiol Res. 2022;71(Suppl 1):S21–S33.
11. Han Y, Liu Z, Chen T. Role of vaginal microbiota dysbiosis in gynecological diseases and interventions. Front Microbiol. 2021;12:643422.
12. Pekmezovic M, Mogavero S, Naglik JR, Hube B. Host-pathogen interactions during female genital infections. Trends Microbiol. 2019;27:982–996.
13. Morsli M, Gimenez E, Magnan C, et al. Lifestyle factors and vaginal microbiota composition. Eur J Clin Microbiol Infect Dis. 2024;43(10):1869–1881.
14. Gilbert NM, Ramirez Hernandez LA, Berman D, et al. Factors linking bacterial vaginosis and infections. J Clin Invest. 2025;135(11):e184322.
15. Dubé-Zinatelli E, Cappelletti L, Ismail N. The vaginal microbiome in bacterial vaginosis. J Reprod Immunol. 2025.
16. Lohova-Matisa E, Rezeberga D, Miskova A. Feminine intimate hygiene: review of habits. Medicina (Kaunas). 2025;61(7):1302.
17. World Health Organization. Sexually transmitted infections (STIs) [Internet].
18. Centers for Disease Control and Prevention. Candidiasis treatment guidelines [Internet].
19. Jenkins SM, Vadakekut ES. Pelvic inflammatory disease. In: StatPearls. 2026.
20. Peters BA, Usyk M, Burk RD. Female microbiome in HIV prevention and disease. Curr Opin HIV AIDS. 2026;21(1):46–51.
21. Da Silva AS, Anwar S, Park S, et al. Vaginal microbiome diagnostics. Front Cell Infect Microbiol. 2025;15:1595182.
22. Wessels JM, Felker AM, Dupont HA, Kaushic C. Sex hormones, vaginal microbiome, and immunity. Dis Model Mech. 2018;11(9):dmm035147.
23. Vodstrcil LA, Twin J, Garland SM, et al. Sexual activity and vaginal microbiota. PLoS One. 2017;12(2):e0171856.
24. Karpinets TV, Solley TN, Mikkelson MD, et al. Effect of antibiotics on microbiomes. Cancer Prev Res. 2020;13(12):997–1006.
25. Chen J, Zhang M, Gong Y, et al. Vaginal microbiome in cervical cancer. Clin Med Insights Oncol. 2025;19:11795549251380470.
26. Pereira MP, Jones S, Costin JM. PCOS and vaginal microbiome dysbiosis. Cureus. 2024;16(6):e62611.
27. Zhang, Y., Wei, T., Zhao, C., & Zhang, L. (2026). The Role of the Vaginal Microbiome in Gynecological Diseases: Mechanistic Insights and Emerging Interventions. Biology, 15(5), 432.
28. Jin C, Liu Z, Li X, et al. Vaginal microbiome in PCOS women. Reprod Biomed Online. 2023.
29. Chudzicka-Strugała I, Gołębiewska I, Banaszewska B, et al. BV and microbiome disorders in PCOS. Diagnostics. 2024;14(4):404.
30. Ahmed DT. Types of vaginal microbiomes in PCOS females. Indian J Obstet Gynecol Res. 2021;8(4):443–447.
31. Coleman JS, Gaydos CA. Molecular diagnosis of bacterial vaginosis. J Clin Microbiol. 2018;56(9):e00342-18.
32. Singer M, Koedooder R, Bos MP, et al. Vaginal microbiota profiling using 16S rRNA sequencing. BMC Microbiol. 2021;21:100.
33. Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci USA. 2011;108(Suppl 1):4680–4687.
34. Srinivasan S, Fredricks DN. Vaginal bacterial biota and bacterial vaginosis. Interdiscip Perspect Infect Dis. 2008;2008:750479.
35. Brotman RM, Klebanoff MA, Nansel TR, et al. Vaginal douching and bacterial vaginosis. Obstet Gynecol. 2008;111(3):756–766.
36. Van de Wijgert JHHM, Jespers V. Global health impact of vaginal dysbiosis. Res Microbiol. 2017;168(9–10):859–864.

37. Sobel JD. Vulvovaginal candidosis. Lancet. 2007;369(9577):1961–1971.
38. Das P, Baker KK, Dutta A, et al. Menstrual hygiene and urogenital infections. PLoS One. 2015;10(6):e0130777.
39. France MT, Mendes-Soares H, Forney LJ. Genomic features of vaginal microbiome. mSystems. 2022;7(1):e0022121.
40. Qi X, Yun C, Pang Y, Qiao J. Gut microbiota and endocrine system. Gut Microbes. 2021;13(1):1–21.
41. Lewis WG, Borree SA, Dzutsev A, et al. Vaginal microbiome and health. Lancet Infect Dis. 2021;21(11):e289–e299.
42. Wang T, Sha L, Li Y, et al. Gut microbiota in PCOS. Front Cell Infect Microbiol. 2022;12:843272.
43. Ata B, Yildiz S, Turkgeldi E, et al. Microbiota in endometriosis. Reprod Sci. 2019;26(10):1364–1373.
44. Ni Z, Sun S, Bi Y, et al. Vaginal microbiota and endometriosis. Front Cell Infect Microbiol. 2020;10:123.
45. Zhang Y, Wei T, Zhao C, Zhang L. Vaginal microbiome in gynecological diseases. Biology. 2026;15(5):432.
46. Workowski KA, Bachmann LH, Chan PA, et al. STI treatment guidelines. MMWR Recomm Rep. 2021;70(4):1–187.
47. Reid G. Probiotic Lactobacilli for urogenital health. Microbiol Spectr. 2017;5(4).
48. Lev-Sagie A, Goldman-Wohl D, Cohen Y, et al. Vaginal microbiome transplantation. Nat Med. 2019;25(10):1500–1504.
49. Kroon SJ, Ravel J, Huston WM. Cervicovaginal microbiota and reproductive outcomes. Fertil Steril. 2018;110(3):327–336.
50. Fettweis JM, Serrano MG, Brooks JP, et al. Vaginal microbiome in women's health. Nat Rev Microbiol. 2019;17(12):777–792.
51. Lagunas-Cruz MC, et al. The vaginal microbiome and host health. Int J Mol Sci. 2026;27(2):640.
52. Hiratsuka D, et al. Reproductive tract microbiome and fertility. Fertil Steril. 2026.
53. Liu S, et al. Exploring vaginal microbiome. Front Microbiol. 2025.
54. Magoutas K, et al. Hygiene practices and microbiome. Front Cell Infect Microbiol. 2025.
55. Sadeghpour Heravi F, et al. Host–microbiota interactions. Curr Obstet Gynecol Rep. 2024.
56. Zhang Q, et al. Targeting vaginal dysbiosis. Front Microbiol. 2026.
57. Schettini G, et al. Microbiota in gynecological disorders. Life (Basel). 2026;16(2):344.